- Second quarter revenue of $26.1 million, an increase of 36% compared to prior year period
- Continued growth from both the Tuberculosis and Tick-borne disease franchises
- Successful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin improvement
- Raising revenue guidance for the full year from $102-$105 million to $103-$106 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced second quarter 2017 financial results.
“We delivered a strong second quarter with revenue growth that exceeded the top end of our guidance range,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “As we continue our evolution from a single-product company to a multi-product company, we are pleased to see solid growth in our core tuberculosis (TB) business as well as a strong contribution from our accelerating tick-borne disease franchise.”
By revenue type, total revenues were, in millions:
